Tissue-type plasminogen activator (t-PA) and dilute blood clot lysis time in nephrotic patients. 1989

M P Cucuianu, and H G Rus, and S Roman, and C Mărcuşu, and C Spînu, and M Manasia, and F Niculescu
Medical Clinic N.I., Cluj-Napoca, Romania.

When compared to normal weight normolipidemic control subjects, dilute blood clot lysis time was found to be obviously (p less than 0.001) prolonged in hypertriglyceridemic patients without proteinuria and slightly (p less than 0.05) accelerated in hyperlipidemic nephrotic patients in spite of their very high levels of plasma fibrinogen. As a result the ratio plasma fibrinogen (mg/dl) per clot lysis time (minutes) was 1.241 +/- 0.08 (X +/- SEM) in control subjects, 0.574 +/- 0.07 in hypertriglyceridemic patients and 2.69 +/- 0.172 in nephrotic patients. This finding suggesting that a larger amount of fibrin is rather readily dispersed from dilute blood clots of nephrotic patients was associated with higher levels of plasma t-PA:Ag (9.45 ng/ml +/- 1.18 in nephrotic patients versus 5.8 ng/ml +/- 1.23 in controls before venous occlusion and respectively 33.1 ng/ml +/- 3.83 versus 20.3 +/- 3.40 in controls after venous occlusion). Plasminogen activator activity of the euglobulins as assessed by the bovine fibrin-agarose plate was significantly higher in nephrotic patients only after venous occlusion. Plasma samples of nephrotic patients exerted a more potent inhibition of fibrinolysis in a urokinase activated system. This effect was, however, mainly due to the high levels of alpha 2 macroglobulin in nephrotic plasma which apparently have little influence on dilute blood clot lysis time.

UI MeSH Term Description Entries
D006951 Hyperlipoproteinemias Conditions with abnormally elevated levels of LIPOPROTEINS in the blood. They may be inherited, acquired, primary, or secondary. Hyperlipoproteinemias are classified according to the pattern of lipoproteins on electrophoresis or ultracentrifugation. Hyperlipoproteinemia
D008297 Male Males
D008875 Middle Aged An adult aged 45 - 64 years. Middle Age
D009401 Nephrosis Pathological processes of the KIDNEY without inflammatory or neoplastic components. Nephrosis may be a primary disorder or secondary complication of other diseases. It is characterized by the NEPHROTIC SYNDROME indicating the presence of PROTEINURIA and HYPOALBUMINEMIA with accompanying EDEMA. Nephroses
D010959 Tissue Plasminogen Activator A proteolytic enzyme in the serine protease family found in many tissues which converts PLASMINOGEN to FIBRINOLYSIN. It has fibrin-binding activity and is immunologically different from UROKINASE-TYPE PLASMINOGEN ACTIVATOR. The primary sequence, composed of 527 amino acids, is identical in both the naturally occurring and synthetic proteases. Alteplase,Plasminogen Activator, Tissue-Type,T-Plasminogen Activator,Tissue-Type Plasminogen Activator,Actilyse,Activase,Lysatec rt-PA,TTPA,Tisokinase,Tissue Activator D-44,Lysatec rt PA,Lysatec rtPA,Plasminogen Activator, Tissue,Plasminogen Activator, Tissue Type,T Plasminogen Activator,Tissue Activator D 44,Tissue Type Plasminogen Activator
D001780 Blood Coagulation Tests Laboratory tests for evaluating the individual's clotting mechanism. Coagulation Tests, Blood,Tests, Blood Coagulation,Blood Coagulation Test,Coagulation Test, Blood,Test, Blood Coagulation
D002784 Cholesterol The principal sterol of all higher animals, distributed in body tissues, especially the brain and spinal cord, and in animal fats and oils. Epicholesterol
D002802 Cholinesterases Acylcholineacylhydrolase,Cholase,Cholinesterase
D005260 Female Females
D005340 Fibrinogen Plasma glycoprotein clotted by thrombin, composed of a dimer of three non-identical pairs of polypeptide chains (alpha, beta, gamma) held together by disulfide bonds. Fibrinogen clotting is a sol-gel change involving complex molecular arrangements: whereas fibrinogen is cleaved by thrombin to form polypeptides A and B, the proteolytic action of other enzymes yields different fibrinogen degradation products. Coagulation Factor I,Factor I,Blood Coagulation Factor I,gamma-Fibrinogen,Factor I, Coagulation,gamma Fibrinogen

Related Publications

M P Cucuianu, and H G Rus, and S Roman, and C Mărcuşu, and C Spînu, and M Manasia, and F Niculescu
June 1987, Thrombosis and haemostasis,
M P Cucuianu, and H G Rus, and S Roman, and C Mărcuşu, and C Spînu, and M Manasia, and F Niculescu
April 1987, Rinsho byori. The Japanese journal of clinical pathology,
M P Cucuianu, and H G Rus, and S Roman, and C Mărcuşu, and C Spînu, and M Manasia, and F Niculescu
August 1986, Thrombosis and haemostasis,
M P Cucuianu, and H G Rus, and S Roman, and C Mărcuşu, and C Spînu, and M Manasia, and F Niculescu
December 1990, Journal of pharmacobio-dynamics,
M P Cucuianu, and H G Rus, and S Roman, and C Mărcuşu, and C Spînu, and M Manasia, and F Niculescu
June 1993, The Journal of cardiovascular surgery,
M P Cucuianu, and H G Rus, and S Roman, and C Mărcuşu, and C Spînu, and M Manasia, and F Niculescu
April 1994, Rinsho byori. The Japanese journal of clinical pathology,
M P Cucuianu, and H G Rus, and S Roman, and C Mărcuşu, and C Spînu, and M Manasia, and F Niculescu
November 1991, Thrombosis and haemostasis,
M P Cucuianu, and H G Rus, and S Roman, and C Mărcuşu, and C Spînu, and M Manasia, and F Niculescu
December 2004, Nihon rinsho. Japanese journal of clinical medicine,
M P Cucuianu, and H G Rus, and S Roman, and C Mărcuşu, and C Spînu, and M Manasia, and F Niculescu
March 1995, Nihon rinsho. Japanese journal of clinical medicine,
M P Cucuianu, and H G Rus, and S Roman, and C Mărcuşu, and C Spînu, and M Manasia, and F Niculescu
December 1993, Therapeutic drug monitoring,
Copied contents to your clipboard!